Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter—still a dilemma?

Por Hegi, Monika E., Stupp, Roger
Publicado no Neuro Oncol (2015)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?

Por Hau, Peter, Stupp, Roger, Hegi, Monika E.
Publicado em 2007

Combining Chromosomal Arm Status and Significantly Aberrant Genomic Locations Reveals New Cancer Subtypes

Por Shay, Tal, Lambiv, Wanyu L., Reiner-Benaim, Anat, Hegi, Monika E., Domany, Eytan
Publicado em 2009

GENETIC AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX GENE SIGNATURE IN GLIOBLASTOMA

Por Hegi, Monika E., Kurscheid, Sebastiann, Sciuscio, Davide, Samarzija, Ivana, Stupp, Roger, Delorenzi, Mauro
Publicado em 2014

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells

Por Johannessen, Tor-Christian Aase, Prestegarden, Lars, Grudic, Amra, Hegi, Monika E., Tysnes, Berit Bølge, Bjerkvig, Rolf
Publicado em 2013

DNA fingerprinting of glioma cell lines and considerations on similarity measurements

Por Bady, Pierre, Diserens, Annie-Claire, Castella, Vincent, Kalt, Stefanie, Heinimann, Karl, Hamou, Marie-France, Delorenzi, Mauro, Hegi, Monika E.
Publicado em 2012

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

Por Weller, Michael, Stupp, Roger, Hegi, Monika E., van den Bent, Martin, Tonn, Joerg C., Sanson, Marc, Wick, Wolfgang, Reifenberger, Guido
Publicado em 2012

Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia

Por Murat, Anastasia, Migliavacca, Eugenia, Hussain, S. Farzana, Heimberger, Amy B., Desbaillets, Isabelle, Hamou, Marie-France, Rüegg, Curzio, Stupp, Roger, Delorenzi, Mauro, Hegi, Monika E.
Publicado em 2009

Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison

Por De Meyer, Tim, Bady, Pierre, Trooskens, Geert, Kurscheid, Sebastian, Bloch, Jocelyne, Kros, Johan M., Hainfellner, Johannes A., Stupp, Roger, Delorenzi, Mauro, Hegi, Monika E., Van Criekinge, Wim
Publicado no Sci Rep (2015)

A Safety Run-in and Randomized Phase II Study of Cilengitide Combined with Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306)

Por Nabors, L. Burt, Mikkelsen, Tom, Hegi, Monika E., Ye, Xiaubu, Batchelor, Tracy, Lesser, Glenn, Peereboom, David, Rosenfeld, Myrna R., Olsen, Jeff, Brem, Steve, Fisher, Joy D., Grossman, Stuart A.
Publicado em 2012

Validation of Real-Time Methylation-Specific PCR to Determine O(6)-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma

Por Vlassenbroeck, Ilse, Califice, Stéphane, Diserens, Annie-Claire, Migliavacca, Eugenia, Straub, Josef, Di Stefano, Ivano, Moreau, Fabrice, Hamou, Marie-France, Renard, Isabelle, Delorenzi, Mauro, Flamion, Bruno, DiGuiseppi, James, Bierau, Katja, Hegi, Monika E.
Publicado em 2008

The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence

Por Lambiv, Wanyu L., Vassallo, Irene, Delorenzi, Mauro, Shay, Tal, Diserens, Annie-Claire, Misra, Anjan, Feuerstein, Burt, Murat, Anastasia, Migliavacca, Eugenia, Hamou, Marie-France, Sciuscio, Davide, Burger, Raphael, Domany, Eytan, Stupp, Roger, Hegi, Monika E.
Publicado em 2011

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction...

Por Bady, Pierre, Sciuscio, Davide, Diserens, Annie-Claire, Bloch, Jocelyne, van den Bent, Martin J., Marosi, Christine, Dietrich, Pierre-Yves, Weller, Michael, Mariani, Luigi, Heppner, Frank L., Mcdonald, David R., Lacombe, Denis, Stupp, Roger, Delorenzi, Mauro, Hegi, Monika E.
Publicado em 2012

Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding...

Por Bady, Pierre, Sciuscio, Davide, Diserens, Annie-Claire, Bloch, Jocelyne, van den Bent, Martin J., Marosi, Christine, Dietrich, Pierre-Yves, Weller, Michael, Mariani, Luigi, Heppner, Frank L., Macdonald, David R., Lacombe, Denis, Stupp, Roger, Delorenzi, Mauro, Hegi, Monika E.
Publicado em 2013

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma

Por Kurscheid, Sebastian, Bady, Pierre, Sciuscio, Davide, Samarzija, Ivana, Shay, Tal, Vassallo, Irene, Criekinge, Wim V, Daniel, Roy T, van den Bent, Martin J, Marosi, Christine, Weller, Michael, Mason, Warren P, Domany, Eytan, Stupp, Roger, Delorenzi, Mauro, Hegi, Monika E
Publicado no Genome Biol (2015)

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

Por Berghoff, Anna Sophie, Kiesel, Barbara, Widhalm, Georg, Rajky, Orsolya, Ricken, Gerda, Wöhrer, Adelheid, Dieckmann, Karin, Filipits, Martin, Brandstetter, Anita, Weller, Michael, Kurscheid, Sebastian, Hegi, Monika E., Zielinski, Christoph C., Marosi, Christine, Hainfellner, Johannes A., Preusser, Matthias, Wick, Wolfgang
Publicado no Neuro Oncol (2015)

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Por Weller, Michael, Nabors, Louis Burt, Gorlia, Thierry, Leske, Henning, Rushing, Elisabeth, Bady, Pierre, Hicking, Christine, Perry, James, Hong, Yong-Kil, Roth, Patrick, Wick, Wolfgang, Goodman, Simon L., Hegi, Monika E., Picard, Martin, Moch, Holger, Straub, Josef, Stupp, Roger
Publicado no Oncotarget (2016)

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, contr...

Por Nabors, L. Burt, Fink, Karen L., Mikkelsen, Tom, Grujicic, Danica, Tarnawski, Rafal, Nam, Do Hyun, Mazurkiewicz, Maria, Salacz, Michael, Ashby, Lynn, Zagonel, Vittorina, Depenni, Roberta, Perry, James R., Hicking, Christine, Picard, Martin, Hegi, Monika E., Lhermitte, Benoit, Reardon, David A.
Publicado no Neuro Oncol (2015)

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Por Gilbert, Mark R., Wang, Meihua, Aldape, Kenneth D., Stupp, Roger, Hegi, Monika E., Jaeckle, Kurt A., Armstrong, Terri S., Wefel, Jeffrey S., Won, Minhee, Blumenthal, Deborah T., Mahajan, Anita, Schultz, Christopher J., Erridge, Sara, Baumert, Brigitta, Hopkins, Kristen I., Tzuk-Shina, Tzahala, Brown, Paul D., Chakravarti, Arnab, Curran, Walter J., Mehta, Minesh P.
Publicado em 2013

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)

Por Baumert, Brigitta G., Hegi, Monika E., van den Bent, Martin J., von Deimling, Andreas, Gorlia, Thierry, Hoang-Xuan, Khê, Brandes, Alba A., Kantor, Guy, Taphoorn, Martin J.B., Hassel, Mohamed Ben, Hartmann, Christian, Ryan, Gail, Capper, David, Kros, Johan M., Kurscheid, Sebastian, Wick, Wolfgang, Enting, Roelien, Reni, Michele, Thiessen, Brian, Dhermain, Frederic, Bromberg, Jacoline E., Feuvret, Loic, Reijneveld, Jaap C., Chinot, Olivier, Gijtenbeek, Johanna M. M., Rossiter, John P., Dif, Nicolas, Balana, Carmen, Bravo-Marques, Jose, Clement, Paul M., Marosi, Christine, Tzuk-Shina, Tzahala, Nordal, Robert A., Rees, Jeremy, Lacombe, Denis, Mason, Warren P., Stupp, Roger
Publicado no Lancet Oncol (2016)